Enterprise Value

9.661B

Cash

1.434B

Avg Qtr Burn

-210.3M

Short % of Float

7.19%

Insider Ownership

34.48%

Institutional Own.

58.52%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

sNDA

Submission

Batoclimab Details
Eye disease , Thyroid Eye Disease

Phase 3

Data readout

Batoclimab Details
Myasthenia gravis

Phase 3

Data readout

Brepocitinib Details
Diabetes mellitus , Systemic lupus erythematosus

Big Mover™

Susp. Mover™

Phase 3

Data readout

RVT-3101 Details
Ulcerative colitis

Phase 3

Initiation

RVT-3101 Details
Crohns disease

Phase 2

Data readout

Phase 2

Data readout

RVT-2001 Details
Myelodysplastic syndrome

Phase 1/2

Data readout